Yasmin - 0.03/3mg 21 Tablets

— contraception.

Trade name: Yasmin

Yasmin

Compound: ethinylestradiol 0.03 mg

drospirenone 3 mg

Auxiliary components: lactose monohydrate, corn starch, pregelatinized corn starch -, povidone K25, magnesium stearate.

Properties: Yasmin® is a low-dose monophasic oral combined estrogen-progestogen contraceptive drug.

The contraceptive effect of combined oral contraceptives (COCs) is based on the interaction of various factors, the most important of which are the suppression of ovulation, increased viscosity of the cervical secretion and changes in the endometrium.

With the correct use of the drug Yasmin®, the Pearl index (an indicator reflecting the number of pregnancies in 100 women using a contraceptive during the year) is less than 1. If you skip pills or misuse, the Pearl index may increase.

In women taking COCs, the menstrual cycle becomes more regular, painful menstrual bleeding is less common, the intensity and duration of bleeding decreases, resulting in a reduced risk of iron deficiency anemia. There is also evidence of a reduced risk of endometrial and ovarian cancer when taking COCs. Drospirenone, which is part of the drug Yasmin®, has antimineralocorticoid activity and can prevent weight gain and the appearance of other symptoms (for example, edema) associated with estrogen-dependent fluid retention. Drospirenone has a positive effect on premenstrual syndrome. In combination with ethinylestradiol, drospirenone shows a favorable effect on the lipid profile, characterized by an increase in HDL. Drospirenone also has antiandrogenic activity and helps reduce acne (acne), oily skin and hair (seborrhea). These features of drospirenone should be considered when choosing a contraceptive for women with hormone-dependent fluid retention, as well as women with acne and seborrhea.

Drospirenone does not have androgenic, estrogenic, glucocorticoid and antiglucocorticoid activity. All this, combined with antimineralocorticoid and antiandrogenic effects, provides drospirenone with a biochemical and pharmacological profile similar to natural progesterone.

Indications: -contraception.

Dosage and administration: The Yasmin® calendar package contains 21 tablets. Each tablet in the package is marked with the day of the week on which it must be taken. Tablets should be taken orally every day for 21 days in the order indicated on the package, at about the same time, with a small amount of water. Taking the tablets from the next package begins after a 7-day break, during which menstrual-like bleeding usually develops («withdrawal» bleeding). As a rule, it begins 2-3 days after taking the last pill and may not end before taking the pills from a new package. After a 7-day break, it is necessary to start taking pills from a new package even if menstrual bleeding has not yet stopped. This means that you need to start taking the pills from a new pack on the same day of the week, and that every month the «withdrawal» bleeding will occur on about the same day of the week.

Start taking Yasmin®

If no hormonal contraceptive has been used in the previous month

Yasmin should be started on the 1st day of the menstrual cycle (i.e. on the 1st day of menstrual bleeding). It is necessary to take a pill that is marked with the corresponding day of the week. Then you should take the pills in order. It is allowed to start taking on the 2-5th day of the menstrual cycle, but in this case it is recommended to additionally use a barrier method of contraception during the first 7 days of taking the tablets from the first package.

Taking missed pills

If the delay in taking the drug was less than 12 hours, contraceptive protection is not reduced. The woman should take the pill as soon as possible, the next pill is taken at the usual time.

If the delay in taking the drug was more than 12 hours, contraceptive protection is reduced. The more pills missed, and the closer the missed pill is to a 7-day pill break, the greater the chance of pregnancy.

In doing so, you must remember:

The drug should never be interrupted for more than 7 days.

7 days of continuous tablet intake is required to achieve adequate suppression of the hypothalamic-pituitary-ovarian system.

Contraindications: — thrombosis (venous and arterial) and thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke), cerebrovascular disorders — currently or in history;

— migraine with focal neurological symptoms at present or in history;

— diabetes mellitus with vascular complications;

— pancreatitis with severe hypertriglyceridemia at present or in history;

— oven

— nocturnal insufficiency and severe liver disease (before normalization of liver tests);

— severe or acute renal failure;

— bleeding from the vagina of unknown origin;

— pregnancy or suspicion of it;

— period of breastfeeding;

Precautionary measures:

An increased risk of thromboembolism in the postpartum period should be taken into account.

Peripheral circulatory disorders can also occur in diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease (Crohn’s disease or ulcerative colitis), and sickle cell anemia.

An increase in the frequency and severity of migraine during the use of COCs (which may precede cerebrovascular disorders) is the basis for the immediate withdrawal of these drugs.

Side effects: Headache, lethargy, drowsiness.

Storage method: At a temperature not higher than 30 degrees. In a dry place.

Package: The carton contains a blister of 21 tablets.